Article

STAR estimates glaucoma risk in a few simple steps

The Scoring Tool for Assessing Risk (STAR) is intended for use in patients with untreated ocular hypertension. It is a cardboard, slide rule-type device featuring two sliding bars (A and B) and three windows.

The Scoring Tool for Assessing Risk (STAR) is intended for use in patients with untreated ocular hypertension. It is a cardboard, slide rule-type device featuring two sliding bars (A and B) and three windows.

To use STAR, clinicians first need to gather the following six pieces of patient data:

With that information in hand, the clinician first pulls bar A to match the patient's age with the IOP in the upper window of STAR. Then, leaving bar A alone, bar B is pulled to match the PSD and CCT values in the middle window. Finally, the vertical C/D ratio value is identified according to whether the patient does or does not have diabetes, and then the clinician reads out the estimated 5-year risk of developing glaucoma in the bottom window relative to the patient's vertical C/D ratio. Risk is reported in ranges of 1% to 5%, 6% to 10%, 11% to 15%, 16% to 20%, 21% to 30%, 31% to 40%, 41% to 50%, and >50%.

The second patient had an IOP of 30 mm Hg, a CCT of 510 µm, no diabetes, a PSD of 1.9 dB, and vertical C/D ratio of 0.4. Using STAR, the 5-year risk for that individual is estimated to be between 41% and 50%.

"During follow-up between 1998 and 2003, the first patient showed no signs of progression to glaucoma based on either optic disc appearance or visual field, and the second individual was one of the patients in our study who showed progression to glaucoma based on optic disc changes that occurred during follow-up from 1992 to 1998," Dr. Medeiros said.

–Cheryl Guttman

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.